Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential

References

• AHMAD, S. R. and WOLFE, S. M., 1995, Cisapride and torsades de pointes. Lancet, 345, 508.
   Web of Science ®Google Scholar
• ANDERSSON, T., MINERS, J. O., VERONESE M. E. and BIRKETT, D. J., 1994, Diazepam metabolism by human liver microsomes is mediated by both s-mephenytoin hydroxylase and CYP3A isoforrns. British Journal of Clinical Pharmacology, 38, 131–137.
   Google Scholar
• ANDERSSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL W., TASSANEEYAKUL W., MEYER, U. A. and BIRKETT, D. J., 1993, Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. British Journal of Clinical Pharmacology, 36, 521–530.
   Google Scholar
• AOYAMA, T., KORZEKWA, K., NAGATA, K., GILLETTE, J., GELBOIN, H. V. and GONZALEZ, F. J., 1990, Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology, 126, 3101–3106.
   PubMed Web of Science ®Google Scholar
• AYRTON J., PLUMB, R., LEAVENS, W. J., MALLETT, D., DICKINS, M. and DEAR, G. J., 1998, Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. Rapid Communications in Mass Spectroscomy,, 12, 217–224.
   Google Scholar
• BACK, D. J., TM, J. F., KARBWANG, J. and COLBERT, J., 1988, In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. British Journal of Clinical Pharmacology, 26, 23–29.
   PubMed Web of Science ®Google Scholar
• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARICE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulfaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261–270.
   PubMed Web of Science ®Google Scholar
• BERTZ, R. J. and GRANNEMAN, G. R., 1997, Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clinical Pharmacokinetics, 32, 210–258.
   PubMed Web of Science ®Google Scholar
• BLOOMER, J. C., CLARKE, S. E. and CHENERY, R. J., 1995, Determination of P4501A2 activity in human liver microsomes using [3-' C-methyl]caffeine. Xenobiotica, 25, 917–927.
   PubMed Web of Science ®Google Scholar
• BLOOMER, J. C., WOODS, F. R., HADDOCK, R. E., LENNARD, M. S. and TUCKER, G. T., 1992, The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. British Journal of Clinical Pharmacology, 33, 521–523.
   PubMed Web of Science ®Google Scholar
• Booms, A. R., McKILL0P, D., ROBINSON, D. T., ADAMS, D. A. and McCoRmicK, D. J., 1998, Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. Xenobiotica, 28, 493–506.
   Google Scholar
• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalysed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321–332.
   PubMed Web of Science ®Google Scholar
• BADLY, F., LIBERSA, C., LHERMITT, M. and DUPUIS, B., 1990, Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes. Biochemical Pharmacology, 39, 1045–1053.
   PubMed Web of Science ®Google Scholar
• BEosEN, K., 1995, Drug interaction and the cytochrome P450 system. Clinical Pharmacokinetics, 29 (suppl. 1), 20–25.
   PubMedGoogle Scholar
• CHANG, T. K. H., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, a-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics, 311,437–422.
   Google Scholar
• CHENG, Y. and PRUSOFF, W. H., 1973, Relationship between the inhibition constant (k) and the concentration of an inhibitor that causes a 50% inhibition (I,) of an enzymatic reaction. Biochemical Pharmacology, 22,3099–3108.
   PubMed Web of Science ®Google Scholar
• CHING, M. S., BLAKE C. L., GHABRIAL, H., WYNNE ELLIS, S., LENNARD, M. S., TUCKER, G. T. and SMALLWOOD, R. A., 1995, Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites. Biochemical Pharmacology, 50,833–837.
   Google Scholar
• CLARKE, S. E., AYRTON, J. C. and CHEERY, R. J., 1994, Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica, 24,517–526.
   PubMed Web of Science ®Google Scholar
• COOK, C. S., HAUSWALD, C., OPPERMANN, J. A. and SCHOENHARD, G. L., 1993, Involvement of cytochrome P4503A in the metabolism of potassium canrenoate to an epoxide: mechanism of inhibition of the epoxide formation by spiranalactone and its sulfur-containing metabolite. Journal of Pharmacology and Experimental Therapeutics, 266,1–7.
   PubMed Web of Science ®Google Scholar
• CRFSPI, C. L., MILLER, V. P. and PENMAN, B. W., 1997, Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Annals of Biochemistry, 248,188–190.
   Web of Science ®Google Scholar
• CRFSPI, C. L. and PENMAN, B. W., 1997, Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug-interactions. Advances in Pharmacology, 43,171–188.
   PubMedGoogle Scholar
• DAYER, P., LEEMANN, T. and STRIBERNI, R., 1989, Dextromethorphan 0-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P450 db activity. Clinical Pharmacology and Therapeutics, 45,34–40.
   PubMed Web of Science ®Google Scholar
• DOECKE, C. J., VERONESE, M. E., POND, S. M., MINERS, J. O., BIRICETT, D. J., SANSOM, L. N. and MEMANus, M. E., 1991, Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. British Journal of Clinical Pharmacology, 31,125–130.
   PubMed Web of Science ®Google Scholar
• DUCHARME, J., ABDULLAH, S. and WAINER, I. W., 1996, Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. Journal of Chromatography B, 678, 113–128.
   PubMed Web of Science ®Google Scholar
• FISCHER, V., VOGELS, B., MAURER, G. and TYNES, R. E.,1992, The antipsychotic clozapine is metabolised by the polymorphic human microsomal and recombinant cytochrome P450 2D6. Journal of Pharmacology and Experimental Therapeutics, 260,1355–1360.
   PubMed Web of Science ®Google Scholar
• FLOCKHART, D. A., 1995, Drug interactions and the cytochrome P450 system. Clinical Pharmacokinetks, 29\(suppl. 1), 45–52.
   PubMedGoogle Scholar
• FONNE -PHSTER, R. and MEYER, U. A., 1988, Xenobiotic and endobiotic inhibitors of cytochrome P450 db1 function, the target of the debrisoquine/sparteine type polymorphism. Biochemical Phar-macology, 37,3829–3835.
   PubMed Web of Science ®Google Scholar
• GASCON, M.-P. and DAYER, P., 1991, In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. European Journal of Clinical Pharmacology, 41,573–578.
   Google Scholar
• GORSKI, J. C., JONES, D. R., WRIGHTON, S. A. and HALL, S. D., 1994, Characterisation of dextro-methorphan N-demethylation by human liver microsomes: contribution of the cytochrome P450 3A subfamily. Biochemical Pharmacology, 48,173–182.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., GILLAM, E. M. J., OHMORI, S., SANDHU, P., BRIAN, W. R., SARI, M. and IWASAKI, M., 1993, Expression of human cytochrome P450 enzymes in yeast and bacteria and relevance to studies on catalytic specificity. Toxicology, 82,21–37.
   Google Scholar
• HA, H. R., CHEN, J., FREIBURGHAUS, A. U. and FOLLATH, F., 1995, Metabolism of theophylline by cDNA-expressed human cytochromes P450. British Journal of Clinical Pharmacology, 39, 321–326.
   PubMed Web of Science ®Google Scholar
• HALLIDAY, R. C., Jos, B. C., SMITH, D. A., KITTERINGHAM, N. R. and PARK, B. K., 1995, An investigation of the interaction between halofantrine CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. British Journal of Clinical Pharmacology, 40,369–378.
   PubMed Web of Science ®Google Scholar
• HONIG, P. K., WORTHAM, D. C., ZAMANI, K., CONNER, D. P., MULLIN, J. C. and CANTILENA, L. R., 1993, Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic conse-quences. Journal of the American Medical Association, 269,1513–1518.
   PubMed Web of Science ®Google Scholar
• JONES, D. R., GORSKI, C., HAEHNER, B. D., O'MARA, E. M. and HALL, S. D., 1996, Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clinical Pharmacology and Therapeutics, 60,374–384.
   Google Scholar
• JACQZ-AIGRAIN, E., FUNCK-BRENTANO, C. and CRESTEIL, T., 1993, CYP2D6 and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics, 3,197–204.
   PubMedGoogle Scholar
• JUNG, F., RICHARDSON, T. H., RAUCY, J. L. and JOHNSON, E. F., 1997, Diazepam metabolism by cDNA-expressed human 2C P450s: identification of P4502C18 and P4502C19 as low Km diazepam N-demethylases. Drug Metabolism and Disposition, 25,133–139.
   PubMed Web of Science ®Google Scholar
• KERRY, N. L., SOMOGYI, A. A., BOCHNER, F. and MIKUS, G., 1994, The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan : in vitro studies using human liver microsomes. British Journal of Clinical Pharmacology, 38, 243–248.
   PubMed Web of Science ®Google Scholar
• KERRY, N. L., SOMOGYI, A. A., MIKUS, G. and BOCHNER, F., 1993, Primary and secondary oxidative metabolism of dextromethorphan : in vitro studies with female Sprague-Dawley and dark agouti rat liver microsomes. Biochemical Pharmacology, 45, 833–839.
   PubMed Web of Science ®Google Scholar
• Ko, J.-W., SUKHOVA, N., THACICER, D., CHEN, P. and FLOCICIIART, D. A., 1997, Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition, 25, 853–862.
   Google Scholar
• KRONBACH, T., MATHYS, D., GUT, J., CATIN, T. and MEYER, U. A., 1987, High-performance liquid chromotographic assays for bufuralol 1.-hydroxylase, debrisoquine 4-hydroxylase and dextro-methorphan 0-demethylase in microsomes and purified cytochrome P450 isozymes of human liver. Annals of Biochemistry, 162, 24–32.
   Web of Science ®Google Scholar
• KIIPFER, A., SCHMID, B., PREISIG, R. and PFAFF, G., 1984, Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet, ii, 517–518.
   Google Scholar
• MANCY, A., BROTO, P., DIJOLS, S., DANSETTE, P. M. and MANSUY, D., 1995, The substrate binding site of human liver cytochrome P4502C9: an approach using designed tienilic acid derivatives and molecular modelling. Biochemistry, 34, 10365–10375.
   PubMed Web of Science ®Google Scholar
• MANCY, A., DIJOLS, S., POLI, S., GUENGERICH, F. P. and MANSUY, D., 1996, Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP2C9. Biochemistry, 35, 16205–16212.
   PubMed Web of Science ®Google Scholar
• MINERS, J. O., COULTER, S., TUKEY, R. H., VERONESE, M. E. and BIRKETT, D. J., 1996, Cytochromes P450, 1A2 and 2C9 are responsible for the human hepatic 0-demethylation of R- and S-naproxen. Biochemical Pharmacology, 51, 1003–1008.
   PubMed Web of Science ®Google Scholar
• NEWTON, D. J., WANG, R. W. and Lu, A. Y. H., 1995, Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
   PubMed Web of Science ®Google Scholar
• OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370–2378.
   PubMed Web of Science ®Google Scholar
• ONO, S., HATANAKA, T., HOTTA, H., SATOH, T., GoNzALEz, F. J. and TSUTSUI, M., 1996a, Specificity of substrate and inhibitor probes for cytochrome P450s : evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotka, 26, 681–693.
   PubMed Web of Science ®Google Scholar
• ONO, S., HATANAKA, T., MIYAZAWA, S., TSUTSUI, M., AOYAMA, T., GONZALEZ, F. J. and SATOH, T., 1996b, Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s : role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica, 26, 1155–1166.
   PubMed Web of Science ®Google Scholar
• PASTRAKULJIC, A., TANG, B. K., ROBERTS, E. A. and KALO W., 1997, Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochemical Phar-macology, 53, 531–538.
   PubMed Web of Science ®Google Scholar
• PECK, C. C., TEMPLE, R. and COLLINS, J. M., 1993, Understanding consequences of concurrent therapies. Journal of the American Medical Association, 269, 1550–1552.
   Web of Science ®Google Scholar
• PICHARD, L., FABRE, I., FABRE, G., DOMERGUE, J., AUBERT, B. S., MOUARD, G. and MAUREL, P., 1990, Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metabolism and Disposition, 18, 595–606.
   PubMed Web of Science ®Google Scholar
• PRITCHARD, P. M., GLANCEY, M. J., BLAKE, J. A. R., GILHAM, D. E., BuRcHELL, B., WOLF, C. R. and FRIEDBERG, T., 1998, Functional co-expression of CYP2D6 and human NADPH-cytochrome P450 reductase in Escherichia coli. Pharmacogenetics, 8, 33–42.
   Google Scholar
• RILEY, R. J. and HOWBROOK, D., 1998, In vitro analysis of the activity of the major human hepatic CYP enzyme (CYP3A4) using [N-methyl ' C]erythromycin. Journal of Pharmacology and Toxicological Methods, 38, 189–193.
   Web of Science ®Google Scholar
• RILEY, R. J., LAMBERT, C., COOPER, A. E., RICHMOND, H., HALL, M., JORDAN, M. C., LOGAN, C. J. and CLARK, B., 1995, Induction of rodent hepatic drug-metabolizing enzyme activities by the novel anticonvulsant remacemide hydrochloride. Drug Metabolism and Disposition, 23, 922–928.
   PubMed Web of Science ®Google Scholar
• RODRIGUES, A. D., 1997, Preclinical drug metabolism in the age of high throughput screening: an industrial perspective. Pharmaceutical Research, 14, 1504–1510.
   PubMed Web of Science ®Google Scholar
• RODRIGUES, A. D., KUKULKA, M. J., ROBERTS, E. M., OUELLET, D. and RODGERS, T. R., 1996, [0-methyl ' C] naproxen 0-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. Drug Metabolism and Disposition, 24, 126–136.
   PubMed Web of Science ®Google Scholar
• RODRIGUES, A. D., KUKULKA, M. J., SURBER, B. W., THOMAS, S. B., UCFIIC, J. T., ROTERT, G. A., MICHEL, G., THOME -KROMER, B. and MACHINIST, J. M., 1994, Measurement of liver microsomal cytochrome P450 (CYP2D6) activity using [0-methyl ' C] dextromethorphan. Annals of Biochemistry, 219, 309–320.
   Google Scholar
• RODIUGUES, A. D., SURBER, B. W., YAO, Y., WONG, S. L. and ROBERTS, E. M., 1997, [0-ethyl ' C] phenacetin 0-deethylase activity in human liver microsomes. Drug Metabolism and Disposition, 25, 1097–1100.
   PubMed Web of Science ®Google Scholar
• ROST, K. L., FUHR, U., ZAIGLER, M., BOHNEMEIER, H. and ROOTS, I., 1995, Omeprazole not only inducers but also inhibits CYP1A2 in man. In 9th International Conference on Cytochrome P450, Pp., -6, p. 47.
   Google Scholar
• SCHMIDER, J., GREENBLATT, D. J., FOGELMAN, S. M., VON MOLTICE, L. L. and SHADER, R. I., 1997, Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharmacology and Drug Disposition, 18, 227–240.
   PubMed Web of Science ®Google Scholar
• SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., MURRAY, S., SEGURA, J., DE LA TORRE, R. and DAVIES, D. S., 1990, Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man. British Journal of Clinical Pharmacology, 29, 651–663.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., YUKIHARU, I. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• TASSANEYAKUL W., BIRKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TUKEY, R. H. and MINERS, J. O., 1994, Direct characterisation of the selectivity of furafylline as an inhibitor of cytochromes P450 1A1 and 1A2. Pharmacogenetics, 4, 281–284.
   PubMedGoogle Scholar
• TASSANEEYAKUL W., BIRKETT, D. J., VERONESE, M. E., MCMANUS, M. E., TUKEY, R. H., QUATTROCHI L. C., GELBOIN, H. V. and MINERS, J. O., 1993, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401–407.
   PubMed Web of Science ®Google Scholar
• TASSANEEYAKUL W., MOHAMED, Z., BIRICETT, D. J., MCMANUS, M. E., VERONESE, M. E., TUKEY, R. H., QUATTROCHI, L. C., GONZALEZ, F. J. and MINERS, J. O., 1992, Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics, 2, 173–183.
   PubMedGoogle Scholar
• TRACY, T. S., MARRA, C., WRIGHTON, S. A., GONZALEZ, F. J. and KORZEKWA, K. R., 1997, Involvement of multiple cytochrome P450s in naproxen 0-demethylation. European Journal of Clinical Pharmacology, 52, 293–298.
   PubMed Web of Science ®Google Scholar
• UENG, Y.-F., KUWBARA, T., CHUN, Y.-J. and GUENGERICH, F. P., 1997, Cooperativity in oxidations catalysed by cytochrome P450 3A4. Biochemistry, 36, 310–381.
   Web of Science ®Google Scholar
• VAN MOLTKE, L. L., GREENBLATT, J. G., GRASSI, J. G., GRANDA, B. W., SCHMIDER, J., HARMATZ, J. S. and SHADER, R. I., 1998, Reevaluation of the specificity of dextromethorphan as an index substrate. Clinical Pharmacology and Therapeutics, 63, 227.
   Web of Science ®Google Scholar
• WATANABE, N., KAMEI, S., OHKUBO, A., YAMANAKA, M., OHSAWA, S., MAKINO, K. and TOKUDA, K., 1986, Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer. Clinical Chemistry, 32, 1551–1554.
   PubMed Web of Science ®Google Scholar
• WIENKERS, L. C., WURDEN, C. J., STORCH, E., KUNZE, K. L., RETTIE, A. E. and TRAGER, W. F., 1996, Formation of (R)-8-hydroxywarfarin in human liver microsomes: a new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metabolism and Disposition, 24, 610–615.
   PubMed Web of Science ®Google Scholar
• Wu, D., OTTON, S. V., MORROW, P., INABA, T., KALOW, W. and SELLERS, E. M., 1993, Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro. Journal of Pharmacology and Experimental Therapeutics, 266, 715–719.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., INouE, K., SHAW, P. M., CHECOVICH, W. J., GUENGERICH, P. and SHIMADA, T., 1997, Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. Journal of Pharmacology and Experimental Therapeutics, 283, 434–442.
   PubMed Web of Science ®Google Scholar
• YANG, C. S., PATTEN, C. J., IsHizmu, H. and Yoo, J. S. H., 1991, Induction, purification and characterisation of cytochrome P450HE. Methods in Enzymology, 206, 595–603.
   PubMed Web of Science ®Google Scholar
• YANG, T. J., SHOU, M., KORZEKWA, K. R., GONZALEZ, F. J., GELBOIN, H. V. and YANG, S. K., 1998, Role of cDNA-expressed human cytochromes P450 in the metabolism of diazepam. Biochemical Pharmacology, 55, 889–896.
   PubMed Web of Science ®Google Scholar
• YASUMORI, T., NAGATA, K., YANG, S. K., CHEN, L.-S., MURAYAMA, N., YAMAZOE, Y. and KATO, R., 1993, Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner. Pharmaco-genetics, 3, 291–301.
   Google Scholar
• ZHANG, X.-J. and THOMAS, P. E., 1996, Erythromycin as a specific substrate for cytochrome P4503A isozyme and identification of a high-affinity erythromycin N-demethylase in adult female rats. Drug Metabolism and Disposition, 24, 23–28.
   PubMed Web of Science ®Google Scholar
• ZHAO, X. J. and Ismzmu, T., 1997, Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes. British Journal of Clinical Pharmacology, 44, 505–511.
   PubMed Web of Science ®Google Scholar
• ZOMORODI, K. and HOUSTON, J. B., 1996, Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. British Journal of Clinical Pharmacology, 42, 157–162.
   PubMed Web of Science ®Google Scholar
• ZOMORODI, K. and HOUSTON, J. B., 1997, Selectivity of omeprazole inhibition towards rat liver cytochromes P450. Xenobiotica, 27, 49–58.
   PubMed Web of Science ®Google Scholar